Filter
160
Text search:
ivermectin
Featured
Recommendations
24
New Publications
35
Language
Document type
No document type
55
Guidelines
41
Studies & Reports
35
Strategic & Response Plan
13
Manuals
7
Fact sheets
6
Training Material
1
Brochures
1
Infographics
1
Countries / Regions
Global
9
Liberia
6
Uganda
6
Latin America and the Carribbean
6
Sierra Leone
5
Ethiopia
5
Germany
5
Brazil
5
India
4
West and Central Africa
4
Middle East and North Africa
4
South Africa
3
Nigeria
2
Tanzania
2
Mozambique
2
East and Southern Africa
2
Africa
2
Congo, Democratic Republic of
1
Philippines
1
South Sudan
1
Zambia
1
Rwanda
1
Yemen
1
Paraguay
1
Solomon Islands
1
Russia
1
Authors & Publishers
Publication Years
Category
Countries
50
Clinical Guidelines
26
Public Health
13
Key Resources
4
Women & Child Health
2
Capacity Building
1
Pharmacy & Technologies
1
Toolboxes
NTDs
51
COVID-19
29
Pharmacy
9
Disability
3
Refugee
3
Mental Health
3
Caregiver
3
Ebola & Marburg
2
HIV
2
Social Ethics
2
Malaria
2
Cholera
1
Conflict
1
AMR
1
doi: https://doi.org/10.1101/2020.11.30.20236570
Pre-Print Article
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin
...
A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications on observational clinical studies reported the apparent utility of
...
Onchocerciasis used to be an important public health problem in Africa, with over 37 million people infected and millions suffering from debilitating skin disease, terrible itching, impaired vision and
blindness. But the epidemiological situation has improved dramatically over the last two decades.
...
Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamaz
...
Tis first edition describes the standard operating procedures for health products for NTDs amenable to preventive chemotherapy and the medicines donated to treat them. These include albendazole for lymphatic filariasis and soil-transmitted helminthiases; azithromycin for trachoma and yaws; diethylca
...
Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 (“the road map”) sets explicit targets for the elimination of onchocerciasis by 2030, including eliminating the need for mass drug administration (MDA) of
...
WHO guideline on preventive chemotherapy for public health control of strongyloidiasis
recommended
Human strongyloidiasis is a chronic parasitic disease caused by infection with Strongyloides stercoralis, a soil-transmitted helminth that is estimated to infect 300–600 million people worldwide. This neglected tropical disease (NTD) is endemic globally, predominately in the South-East Asia, Afric
...
The Onchocerciasis Control Programme in West Africa (OCP) undertook regional and large scale frght against onchocerciasis in West Africa in 1974 using a vector control strategy. By 2002 OCP had succeeded in eliminating the disease as a public health, socio-economic and development problem in 10 out
...
A living WHO guideline on drugs for covid-19
recommended
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE
...
The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown
...
In South and Central America, lymphatic filariasis (LF) is caused by Wuchereria bancrofti, which is transmitted by Culex quinquefasciatus, the only vector species in this region. Of the seven countries considered endemic for LF in the Americas in the last decade, Costa Rica, Suriname and Trinidad a
...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for
...
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement
...
3 March 2022
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an
...
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi
...
Onchocerciasis – or “river blindness” – is a parasitic disease caused by the filarial worm
Onchocerca volvulus. It is transmitted through the bites of infected blackflies (Simulium spp.) that
breed in fast-flowing rivers and streams, mostly in remote villages located near fertile land wher
...
